# ELIXIR PHARMATECH

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/elixir-pharmatech

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.elixirpharmatech.com
- Total disclosed funding: $1.2M
- Latest round: Seed (Dec 24, 2023)
- Investors on record: 2

## About

Based in Seoul, South Korea, and founded in 2021 by Chief Executive Officer Lee Dong-yoon, Ilixa Pharmatech Co., Ltd. doing business as Elixir Pharmatech operates as a manufacturing company providing medical drugs that are studied to provide solutions to gastrointestinal tract inflammations. In December 2023, ELIXIR PHARMATECH raised KRW 1.5 billion in seed funding from Kingsley Ventures, with participation from Korea Tech Incubator for Startup, being selected for Accelerator Investment-Driven Tech Incubator Program.

Elixir Pharmatech manufactures immuno-inflammatory drugs through genetic manipulation and expression. The company’s medicine is developed through a variety of derivatives based on various small molecules, natural products, polysaccharides, polymers, inorganic nanoparticles, and many more. In addition, the firm provides synthetic drugs and peptide drugs for curing intestinal membrane.

## Funding rounds

- Seed, Dec 24, 2023 — Kingsley Ventures
- Seed, Dec 24, 2023, $1.2M — Korea Tech Incubator for Startup, Kingsley Ventures

## Investors

- Kingsley Ventures (https://capitalatlas.ai/funds/kingsley-ventures) — Seed
- Korea Tech Incubator for Startup — Seed